Victoria Barbosa, MD: Alopecia Areata in Skin of Color

Dr. Victoria Barbosa recaps her presentation on alopecia areata in patients with skin of color, covering prevalance, diagnostic challenges, and treatment considerations. She notes that research indicates higher rates of alopecia areata in this population, with data suggesting additional factors such as hair color may also be relevant. Dr. Barbosa reviews common diagnostic challenges and conditions that can mimic or coexist with alopecia areata and emphasizes the importance of a careful clinical evaluation. Dr. Barbosa also explores how trust and shared decision-making can help patients navigate discussions about newer treatment options, including JAK inhibitors, while underscoring the value of patient education and community support throughout the treatment journey.

MORE NAAF CONFERENCE COVERAGE 2026:

Joanna Rosen, PsyD: Perspectives on Parenting a Child With Alopecia Areata

Dr. Joanna Rosen discusses the emotional impact that alopecia areata can have on families, drawing on her experiences as both a clinical psychologist specializing in

Joseph Fakhoury, MD: Ask the Experts for Adults with Alopecia Areata

Dr. Joseph Fakhoury discusses what patients can expect during treatment for alopecia areata, offering guidance on response timelines. He explains that responses to Janus kinase

Victoria Mattingly, PhD: Alopecia in the Workplace

Dr. Victoria Mattingly discusses how individuals living with alopecia areata can navigate the workplace through authenticity, confidence, and intentional allyship. She emphasizes that each person

Joseph Fakhoury, MD: Current and Emerging Treatments in Alopecia Areata

Dr. Joseph Fakhoury provides an overview of the current treatment landscape for alopecia areata, reviewing approved Janus kinase (JAK) inhibitors for adolescents and adults, along

Joseph Fakhoury, MD: Patient Perspectives in Alopecia Areata

Dr. Joseph Fakhoury moderated a patient panel exploring the real-world experience of living with alopecia areata and treatment with Janus kinase (JAK) inhibitors. Panelists discussed